ReviewPharmaceuticals (Basel, Switzerland)2021
The Age of Phage: Friend or Foe in the New Dawn of Therapeutic and Biocontrol Applications?
Review in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Bacteriophages of Thermophilic 'International journal of molecular sciences · 2024Pooled it
- UropathogenicAntibiotics (Basel, Switzerland) · 2026Review
- Isolation and therapeutic potential of phage vB_EcoM_GXW16 against a drug-resistant avian pathogenic Escherichia coli strain.Poultry science · 2026Article
- Limitations and safety aspects related to the use of bacteriophages in food production.FEMS microbiology reviews · 2026Article
- The Emerging Role of Dietary Bacteriophage in Monogastric Animals in the Post-Antibiotic Era-A Review.Veterinary sciences · 2025Review
- Multi-omics characterization of a lytic phage targetingmSystems · 2025Article
- Enhancing phage therapy by coating single bacteriophage-infected bacteria with polymer to preserve phage vitality.Nature biomedical engineering · 2025Article
- Current Clinical Laboratory Challenges to Widespread Adoption of Phage Therapy in the United States.Antibiotics (Basel, Switzerland) · 2025Review
- Disruption ofMicrobiology (Reading, England) · 2025Article
- Anti-Infective Bacteriophage Immobilized Nitric Oxide-Releasing Surface for Prevention of Thrombosis and Device-Associated Infections.ACS applied bio materials · 2025Article
- What, how, and why? - anti-EHEC phages and their application potential in medicine and food industry.Journal of applied genetics · 2025Review
- Non-antibiotic therapies for multidrug-resistant gastrointestinal infections: an overview of the use of probiotics, natural compounds, and bacteriophages.Frontiers in antibiotics · 2025Review
- Molecular characterization and safety properties of multi drug-resistant Escherichia coli O157:H7 bacteriophages.BMC microbiology · 2024Article
- Therapeutic Phage Candidates for Targeting Prevalent Sequence Types of Carbapenem-ResistantFoodborne pathogens and disease · 2024Article
- A Critical Analysis of the Opportunities and Challenges of Phage Application in Seafood Quality Control.Foods (Basel, Switzerland) · 2024Review
- Synergistic Antimicrobial Effects of Phage vB_AbaSi_W9 and Antibiotics againstAntibiotics (Basel, Switzerland) · 2024Article
- Benefits and Challenges of Applying Bacteriophage Biocontrol in the Consumer Water Cycle.Microorganisms · 2024Review
- Phage-specific immunity impairs efficacy of bacteriophage targeting Vancomycin Resistant Enterococcus in a murine model.Nature communications · 2024Article
- Recombinant TP-84 Bacteriophage Glycosylase-Depolymerase Confers Activity against ThermostableInternational journal of molecular sciences · 2024Article
- Bacteriophage-mediated approaches for biofilm control.Frontiers in cellular and infection microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Extended overuse and misuse of antibiotics and other antibacterial agents has resulted in an antimicrobial resistance crisis. Bacteriophages, viruses that infect bacteria, have emerged as a legitimate alternative antibacterial agent with a wide scope of applications which continue to be discovered and refined. However, the potential of some bacteriophages to aid in the acquisition, maintenance, and dissemination of negatively associated bacterial genes, including resistance and virulence genes, through transduction is of concern and requires deeper understanding in order to be properly addressed. In particular, their ability to interact with mobile genetic elements such as plasmids, genomic islands, and integrative conjugative elements (ICEs) enables bacteriophages to contribute greatly to bacterial evolution. Nonetheless, bacteriophages have the potential to be used as therapeutic and biocontrol agents within medical, agricultural, and food processing settings, against bacteria in both planktonic and biofilm environments. Additionally, bacteriophages have been deployed in developing rapid, sensitive, and specific biosensors for various bacterial targets. Intriguingly, their bioengineering capabilities show great promise in improving their adaptability and effectiveness as biocontrol and detection tools. This review aims to provide a balanced perspective on bacteriophages by outlining advantages, challenges, and future steps needed in order to boost their therapeutic and biocontrol potential, while also providing insight on their potential role in contributing to bacterial evolution and survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.